Literature DB >> 3121594

Biochemical and functional analysis of soluble human interleukin-2 receptor produced in rodent cells. Solid-phase reconstitution of a receptor-ligand binding reaction.

J Hakimi1, C Seals, L E Anderson, F J Podlaski, P Lin, W Danho, J C Jenson, A Perkins, P E Donadio, P C Familletti.   

Abstract

The binding of interleukin-2 (IL-2) to the IL-2 receptor (IL-2R) on human T-cells is a key regulatory event which is absolutely required for T-cell-mediated immune responses. To understand further this binding event, we modified the human IL-2R gene to encode a secreted form of IL-2R. Secreted IL-2R was then expressed at very high levels (approximately 11 micrograms/10(6) cells/48 h) in rodent cells using gene-linked co-amplification. The soluble forms of IL-2R were shown to retain IL-2 affinity shown by cell-surface IL-2R (Kd approximately 18 nM) and were purified to homogeneity using IL-2 affinity chromatography. Purified, recombinant IL-2R and biotinylated IL-2 were used to establish a solid-phase receptor binding assay. Binding of IL-2-biotin was demonstrated to be dose-dependent at concentrations ranging from 10 to 1000 ng/ml, and the specificity of receptor-ligand binding was demonstrated by competition with non-biotinylated IL-2 and with anti-receptor antibodies known to block IL-2 binding in vivo. This immunosorbent receptor assay offers a simple and rapid method for studying the binding of IL-2 to human IL-2R.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3121594

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival.

Authors:  P S Brown; G L Parenteau; F M Dirbas; R J Garsia; C K Goldman; M A Bukowski; R P Junghans; C Queen; J Hakimi; W R Benjamin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

2.  Identification of specific residues of human interleukin 2 that affect binding to the 70-kDa subunit (p70) of the interleukin 2 receptor.

Authors:  L Collins; W H Tsien; C Seals; J Hakimi; D Weber; P Bailon; J Hoskings; W C Greene; V Toome; G Ju
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

3.  Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial.

Authors:  R B Nussenblatt; E Fortin; R Schiffman; L Rizzo; J Smith; P Van Veldhuisen; P Sran; A Yaffe; C K Goldman; T A Waldmann; S M Whitcup
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

4.  Identification of a direct interaction between interleukin 2 and the p64 interleukin 2 receptor gamma chain.

Authors:  S D Voss; T P Leary; P M Sondel; R J Robb
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

5.  Plasma interleukin-2 and a soluble/shed interleukin-2 receptor in serum of patients with Crohn's disease. Effect of cyclosporin.

Authors:  J Brynskov; N Tvede
Journal:  Gut       Date:  1990-07       Impact factor: 23.059

6.  Soluble interleukin-2 receptors in ulcerative colitis.

Authors:  O H Nielsen; J Brynskov
Journal:  Mediators Inflamm       Date:  1993       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.